UCB agreed to acquire Neurona Therapeutics for up to $1.2 billion, positioning the Belgian drugmaker to move beyond its small-molecule core into seizure cell therapy. The deal adds an investigational therapy in early testing for a difficult-to-treat epilepsy subtype, complementing UCB’s established franchise in neurologic disorders. For investors, the headline is diversification: the company is pairing targeted cell-based development with its traditional emphasis on medicine chemistry and clinical development scale. For the field, it underscores the acceleration of specialty therapy platforms into CNS categories where unmet need remains high. If clinical differentiation holds, the acquisition could become a template for how mid-to-large biopharmas buy early-stage modalities to build optionality ahead of later competition and patent calendars.